Investors Face August 3 Deadline in GeneDx Securities Fraud Lawsuit

The litigation alleges that GeneDx misled shareholders regarding the integration of its Fabric acquisition. Throughout the class period, the company claimed the merger would enhance financial performance and optimize dry lab processes through improved algorithms. The lawsuit asserts these representations were false, claiming defendants either knew of or recklessly disregarded significant viability issues within the Fabric unit that threatened overall business operations. When these realities surfaced, shareholders allegedly suffered financial losses.

Investors are not required to serve as lead plaintiff to participate in any potential future recovery, nor are they currently represented by counsel unless they specifically retain a firm. Those wishing to participate or seeking additional information may contact Phillip Kim at the Rosen Law Firm. The firm, which highlights its history in securities litigation and past settlements, emphasizes that investors have the right to select their own legal representation.